Get Connected:

 

Latest News

Cannabis Could Treat Dementia, Cognitive Decline
Low-dose THC reversed brain aging in mice.
Age-associated B cells found to contribute to autoimmune disorder prevalence in women.
Adult and pediatric multiple sclerosis may have similar risk factors.
Top news of the day from across the healthcare landscape.
Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in older people.
Viagra and other PDE5 inhibitors found safe as long as men are not also taking nitrates.
Dark adaptation testing has been shown to be better than visual acuity testing in diagnosing and staging AMD.  
Pembrolizumab targets the PD-1/PD-L1 cellular pathway to help the immune system fight cancer cells.
View More >

From the Journals

Adherence and access to higher-value care can make a big difference in reducing costs for patients and our healthcare system; however, the financial burden of high-deductible health plans and out-of-pocket costs must also be considered.

Patients with multiple chronic conditions are less likely to use generic drugs, even when facing lower co-payments.

A telephonic pharmacist-delivered medication therapy management intervention is an effective method for increasing the utilization of guideline-recommended cardiovascular therapies in high-risk Medicare patients with diabetes.

A controlled trial of a system for rectifying and preventing drug-related problems was conducted to evaluate improvement in the efficiency of resource utilization.

In addition to having a major impact on patient health outcomes, medications can have significant cost implications for all stakeholders; insurers and employers need to work with their pharmacy benefit managers to ensure that the right patients are getting the right medications at the right time.

Having the right evidence, using high-value care, and developing strong incentives to improve payment and delivery systems are among the ways we can improve healthcare.
This analytic model assessed the per-woman cost differences between the use of 2 levonorgestrel-releasing intrauterine devices, from a US payer perspective.
Upcoming Partner Events